Paris & Boston, September 30, 2019 - 08h30am CEST - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of auto-immune diseases, has today announced, the appointment of Vincent Serra, PhD, as the new Chief Executive Officer, with immediate effect, to succeed Miguel Sieler who has resigned as CEO and as a board director.

Jean-Jacques Bertrand, President of the Neovacs Board of Directors declared: 'On behalf of the Board of Directors I am delighted to welcome Vincent Serra as the CEO. Vincent has the leadership qualities and operational experience needed to carry our innovative kinoid technology forward to the market and to contribute to the overall success of the company.'

Attachments

  • Original document
  • Permalink

Disclaimer

Neovacs SA published this content on 01 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 October 2019 12:57:10 UTC